Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Assets (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Current Assets for 13 consecutive years, with $608.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 29.77% year-over-year to $608.2 million; the TTM value through Mar 2026 reached $608.2 million, down 29.77%, while the annual FY2025 figure was $715.6 million, 21.12% down from the prior year.
  • Current Assets hit $608.2 million in Q1 2026 for Viking Therapeutics, down from $715.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $966.3 million in Q1 2024 and bottomed at $149.5 million in Q1 2023.
  • Average Current Assets over 5 years is $559.7 million, with a median of $608.2 million recorded in 2026.
  • Year-over-year, Current Assets surged 546.52% in 2024 and then fell 29.77% in 2026.
  • Viking Therapeutics' Current Assets stood at $167.0 million in 2022, then surged by 119.84% to $367.2 million in 2023, then soared by 147.05% to $907.2 million in 2024, then fell by 21.12% to $715.6 million in 2025, then dropped by 15.01% to $608.2 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $608.2 million, $715.6 million, and $738.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.